1. Journal Papers

This table browses all dspace content
Issue DateTitleJournal Title
2025X-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
2025Current Practices in Monitoring Children and Adults With X-linked Hypophosphatemia: A Global Survey of Expert Experience JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
2025X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
2025Best practice recommendations for the diagnosis and management of hypoparathyroidism METABOLISM-CLINICAL AND EXPERIMENTAL
2025KRASG12D selective VHL-PROTAC with sparing KRASWT and other KRAS mutantsEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
2025Temporal trends in ischemic stroke and female sex as a risk modifier in atrial fibrillation: insights from non-anticoagulated Asian patients in a nationwide cohort study LANCET REGIONAL HEALTH-WESTERN PACIFIC
2025BACES score: a predictor of health-related quality of life and associated factors in patients with nontuberculous mycobacterial pulmonary disease SCIENTIFIC REPORTS
2025Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0 CLINICAL AND MOLECULAR HEPATOLOGY
2025Trends and management of acute respiratory failure in hospitalized patients: a multicenter retrospective study in South Korea ACUTE AND CRITICAL CARE
2025Tarlatamab in Small-Cell Lung Cancer after Platinum-Based ChemotherapyNEW ENGLAND JOURNAL OF MEDICINE
2025Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung CancerNEW ENGLAND JOURNAL OF MEDICINE
2025Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset LUNG CANCER
2025ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJCO PRECISION ONCOLOGY
2025Discovery of BBT-176 as a fourth-generation EGFR tyrosine kinase inhibitorResults in Chemistry
2025Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer LUNG CANCER
2025Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA FUTURE ONCOLOGY
2025Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A JOURNAL OF THORACIC ONCOLOGY
2025Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study JOURNAL OF CLINICAL ONCOLOGY
2025Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC CANCERS
2025First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial JOURNAL OF CLINICAL ONCOLOGY

Recent Submissions

Browse

Links